Unicycive Therapeutics, Inc. (UNCY) Stock Price & Analysis
Unicycive Therapeutics, Inc. (UNCY) rose 0.99% to USD 5.08 as of September 9, 2026 at 15:29 UTC, according to Nexqual real-time market data.
UNCY last closed at USD 5.08; the session ranged USD 5.01–5.09 on volume of 345,205 shares. Market capitalization is —, with a 52-week range of USD 3.71–8.74 (NCM). Source: Nexqual, September 9, 2026 at 15:29 UTC.
Key Statistics (as of September 9, 2026 at 15:29 UTC)
| Price | USD 5.08 |
|---|---|
| Change | ▲ 0.99% (up) |
| Previous Close | USD 5.08 |
| Open | USD 5.08 |
| Day Range | USD 5.01 – 5.09 |
| 52-Week Range | USD 3.71 – 8.74 |
| Volume | 345,205 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (UNCY)
Nexqual's technical model rates UNCY "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of September 9, 2026 at 15:29 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 42.59 (neutral) |
| vs SMA50 | Below (USD 5.27) |
| MACD | -0.09 (negative) |
Analyst Ratings (UNCY)
Wall Street analysts rate UNCY "None" based on 9 analysts, with a mean price target of USD 28.22 (range USD 15–50), per Nexqual as of September 9, 2026 at 15:29 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 28.22 |
| High Target | USD 50 |
| Low Target | USD 15 |
| Buy / Hold / Sell | 9 / 0 / 0 |
Earnings (UNCY)
| Next Earnings Date | 2026-11-12 |
|---|---|
| EPS Estimate | USD -0.31 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.06 vs est -0.33 ▲ beat |
| 2025-12-31 | USD -0.82 vs est -0.46 ▼ miss |
| 2025-09-30 | USD -0.33 vs est -0.53 ▲ beat |
Source: Nexqual, September 9, 2026 at 15:29 UTC.
Financials & Fundamentals (UNCY)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -101.07% |
| Debt / Equity | 1.26 |
| Current Ratio | 3.81 |
| Total Cash | $61.42M |
| Total Debt | $671,000 |
| Free Cash Flow | $-12.72M |
Source: Nexqual, September 9, 2026 at 15:29 UTC.
Financial Health Score (UNCY)
Nexqual rates Unicycive Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of September 9, 2026 at 15:29 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $61M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$28M |
| Efficiency | Critical — ROE -101%, ROA -40.6% |
Ownership (UNCY)
| Insider Ownership | +2.26% |
|---|---|
| Institutional Ownership | +42.25% |
| Shares Outstanding | 27.39M |
| Float | 27.23M |
| Short % of Float | +15.25% |
Source: Nexqual, September 9, 2026 at 15:29 UTC.
Leadership (UNCY)
Unicycive Therapeutics, Inc. is led by Shalabh K. Gupta M.D., MPA (age 52), Founder, Chairman, CEO & President, per Nexqual as of September 9, 2026 at 15:29 UTC.
| Founder, Chairman, CEO & President | Shalabh K. Gupta M.D., MPA (age 52) |
|---|---|
| Executive Vice President of Pharmaceutical and Business Operations | Pramod Gupta (age 65) |
| Executive Vice President of Corporate Strategy | Douglas Jermasek (age 64) |
| Chief Financial Officer | John W. Townsend (age 63) |
Major Backers & Investors (UNCY)
Notable institutional backers of Unicycive Therapeutics, Inc. include Nantahala Capital Management, LLC, Octagon Capital Advisors LP, Marshall Wace LLP, according to Nexqual as of September 9, 2026 at 15:29 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Nantahala Capital Management, LLC | 5.03% |
| Octagon Capital Advisors LP | 3.59% |
| Marshall Wace LLP | 1.97% |
| Vivo Capital, LLC | 1.97% |
| Logos Global Management LP | 1.7% |
| Diametric Capital, Lp | 1.34% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.29% |
| Vanguard Group | 7.6% |
| Geode Capital | 2.02% |
| State Street | 1.62% |
Source: Nexqual, September 9, 2026 at 15:29 UTC.
From Unicycive Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- In September 2024, we submitted a New Drug Application (NDA) for OLC to the FDA.
- We completed both studies and submitted the data for the FDA's review during the pre-NDA (New Drug Application) meeting request.
- Our technology for UNI-494 is licensed from Sphaera Pharmaceutical Private Limited, a Singapore-based company ("Sphaera"), with offices in India and the U.S.
Partnerships
- In select Asian markets, we have entered into a licensing agreement with Lotus Pharmaceutical Co., Ltd., which is responsible for regulatory filings, commercialization, and distribution within its designated regions.
- If and when any of our product candidates are approved, we plan to obtain manufacturing capacity through contract manufacturing organizations (CMOs) to meet projected needs for commercial sale quantities and serve patient needs.   With regards to manufacturing, testing and potential commercial supply of oxylanthanum carbonate, on October 31, 2020, the Company entered into an agreement with Shilpa Medicare Ltd ("Shilpa") based in India.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RNAZ | TransCode Therapeutics, Inc. | USD 1.91 | ▼ 7.28% |
| INAB | IN8bio, Inc. | USD 1.12 | ▼ 6.67% |
| PALI | Palisade Bio, Inc. | USD 2.11 | ▲ 0.72% |
| DRMA | Dermata Therapeutics, Inc. | USD 1.26 | ▲ 4.13% |
| ENSC | Ensysce Biosciences, Inc. | USD 0.48 | ▲ 5.26% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 15:29 UTC. This page is informational and not investment advice.